The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Published

Journal Article

As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

Full Text

Duke Authors

Cited Authors

  • Experts in Chronic Myeloid Leukemia,

Published Date

  • May 30, 2013

Published In

Volume / Issue

  • 121 / 22

Start / End Page

  • 4439 - 4442

PubMed ID

  • 23620577

Pubmed Central ID

  • 23620577

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2013-03-490003

Language

  • eng

Conference Location

  • United States